UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 4,
2018
MONOPAR THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
Delaware
|
000-55866
|
32-0463781
|
(State or other jurisdiction
|
(Commission
|
(I.R.S. Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
1000 Skokie Blvd., Suite 350, Wilmette, IL
|
|
60091
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(847) 388-0349
Registrant’s telephone number, including area
code
N/A
(Former name or former address, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
☐ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security
Holders.
On June
4, 2018, Monopar Therapeutics Inc. (the “Company”) held
its 2018 annual meeting of stockholders. A total of 9,291,420.614
shares of the Company’s common stock were entitled to vote as
of April 19, 2018, the record date for the 2018 annual meeting, of
which 7,361,339.6 shares were represented in person or by proxy at
the 2018 annual meeting. At the 2018 annual meeting, the
stockholders of the Company voted on the following
proposals:
(1) the
election of six directors, to serve as directors until the
Company’s next annual meeting of stockholders or until their
respective successors are duly elected and qualified;
and
(2) the
ratification of the selection of BPM LLP as the Company’s
independent registered public accounting firm for the year ending
December 31, 2018.
Proposal 1 – Election of Directors
At the
2018 annual meeting, the voting results with respect to the
proposal for the election of directors, included in the
Company’s Information Statement on Schedule 14C for the
annual meeting of stockholders, were as follows:
Director
|
For
|
Against
|
Withheld
|
Abstained
|
Broker Non-Votes
|
Christopher M.
Starr, Ph.D.
|
7,361,339.6
|
0
|
0
|
0
|
0
|
Chandler
D. Robinson, MD MBA MSc
|
7,361,339.6
|
0
|
0
|
0
|
0
|
Andrew
P. Mazar, Ph.D.
|
7,361,339.6
|
0
|
0
|
0
|
0
|
Michael
J. Brown, MSc
|
7,361,339.6
|
0
|
0
|
0
|
0
|
Raymond
“Bill” Anderson, MBA
|
7,361,339.6
|
0
|
0
|
0
|
0
|
Arthur
Klausner, MBA
|
7,361,339.6
|
0
|
0
|
0
|
0
|
Proposal 2 – Ratification of Selection of Independent
Registered Public Accounting Firm
The
voting results with respect to the proposal to ratify the selection
of BPM LLP to serve as the Company’s independent registered
public accountant for the year ending December 31, 2018 were as
follows:
For
|
Against
|
Withheld
|
Abstained
|
Broker Non-Votes
|
7,347,336.8
|
14,002.8
|
0
|
0
|
0
|
Accordingly, the
Company stockholders ratified the selection of BPM LLP to serve as
the Company’s independent registered public accountant for
the year ending December 31, 2018.
No
other matters were submitted to a vote of stockholders at the 2018
annual meeting.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Monopar
Therapeutics Inc.
|
By: /s/ Kim R.
Tsuchimoto
|
Name: Kim R. Tsuchimoto
|
Title: Chief Financial Officer, Secretary and
Treasurer
|
Date:
June 4, 2018